• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Trevi Therapeutics Inc.

    3/18/25 4:16:59 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    S-8 1 2025_s-8_-_annual_share_.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 18, 2025

    Registration Statement No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    Trevi Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    45-0834299

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    195 Church Street, 16th Floor

    New Haven, CT 06510

    (Address of principal executive offices)

    2019 Stock Incentive Plan

    (Full title of the plan)

    Jennifer Good

    President and Chief Executive Officer

    Trevi Therapeutics, Inc.

    195 Church Street, 16th Floor

    New Haven, Connecticut 06510

    (Name and address of agent for service)

    (203) 304-2499

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

     

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    Statement of Incorporation by Reference

    This Registration Statement on Form S-8, relating to the 2019 Stock Incentive Plan (the "2019 Plan") of Trevi Therapeutics, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference (i) the contents of the Registration Statement on Form S-8, File No. 333-231260, relating to the 2012 Stock Incentive Plan, as amended, of the Registrant, the 2019 Plan, and the 2019 Employee Stock Purchase Plan of the Registrant (the “2019 ESPP”), filed by the Registrant with the Securities and Exchange Commission on May 7, 2019, (ii) the contents of the Registration Statement on Form S-8, File No. 333-237193, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on March 16, 2020, (iii) the contents of the Registration Statement on Form S-8, File No. 333-257729, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on July 7, 2021, (iv) the contents of the Registration Statement on Form S-8, File No. 333-264615, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on May 2, 2022, (v) the contents of the Registration Statement on Form S-8, File No. 333-271839, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on May 11, 2023, and (vi) the contents of the Registration Statement on Form S-8, File No. 333-278101, relating to the 2019 Plan, filed by the Registrant with the Securities and Exchange Commission on March 20, 2024.

     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Number

    Description

    4.1(1)

    Restated Certificate of Incorporation of the Registrant, as amended

    4.2(2)

    Amended and Restated Bylaws of the Registrant

    5.1

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

    23.1

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

    23.2

    Consent of Ernst & Young LLP, independent registered public accounting firm

    24.1

    Power of attorney (included on the signature pages of this registration statement)

    99.1(3)

    2019 Stock Incentive Plan

    107

    Filing Fee Table

    ____________

    (1)
    Previously filed with the Securities and Exchange Commission on August 10, 2023 as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38886) and incorporated herein by reference.
    (2)
    Previously filed with the Securities and Exchange Commission on April 14, 2023 as an Exhibit to the Registrant’s Current Report on Form 8-K (File No. 001-38886) and incorporated herein by reference.
    (3)
    Previously filed with the Securities and Exchange Commission on April 5, 2019 as an Exhibit to the Registrant’s Registration Statement on Form S-1 (File No. 333-230745) and incorporated herein by reference.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New Haven, Connecticut, on this 18th day of March, 2025.

     

     

    Trevi Therapeutics, Inc.

    By:

    /s/ Lisa Delfini

    Name:

    Lisa Delfini

    Title:

    Chief Financial Officer

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Trevi Therapeutics, Inc., hereby severally constitute and appoint Jennifer Good and Lisa Delfini, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Trevi Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

     

     

    /s/ Jennifer Good

    President and Chief Executive Officer, Director

    (Principal Executive Officer)

    March 18, 2025

    Jennifer Good

     

     

     

     

    /s/ Lisa Delfini

    Chief Financial Officer

    (Principal Financial Officer)

    March 18, 2025

    Lisa Delfini

     

     

     

     

    /s/ Christopher Galletta

    Controller

    (Principal Accounting Officer)

    March 18, 2025

    Christopher Galletta

     

     

     

     

     

     

     

    /s/ David Meeker, M.D.

    Chairman of the Board

    March 18, 2025

    David Meeker, M.D.

     

     

     

     

    /s/ Dominick Colangelo

    Director

    March 18, 2025

    Dominick Colangelo

     

     

     

     

    /s/ Michael Heffernan

    Director

    March 18, 2025

    Michael Heffernan

     

     

     

     

    /s/ Edward Mathers

    Director

    March 18, 2025

    Edward Mathers

     

     

     

     

    /s/ Anne VanLent

    Director

    March 18, 2025

    Anne VanLent

     

     

     

     

     

     

     


    Get the next $TRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    8/30/2024$6.00Buy
    H.C. Wainwright
    8/30/2024$9.00Outperform
    Raymond James
    6/13/2024$7.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TRVI
    Financials

    Live finance-specific insights

    See more
    • Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)

      5/8/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

      Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2025. www.trevith

      5/1/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

      Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Managemen

      3/18/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/14/24 5:51:58 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/13/24 4:30:24 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

      SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/8/24 6:57:55 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    See more

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

      NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

      9/30/24 5:30:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

      Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d

      4/2/24 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00

      5/28/25 9:09:46 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously

      3/10/25 8:08:41 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Trevi Therapeutics with a new price target

      Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $25.00 from $8.00 previously

      3/10/25 7:49:08 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Participate in Upcoming June Conferences

      NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">

      5/29/25 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

      Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn., May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66). In March 2025, the Company announced positive topline results, where Haduvio met the primary endpoint with a statist

      5/20/25 7:00:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)

      5/8/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Sciascia Thomas exercised 2,631 shares at a strike of $1.43 and sold $17,365 worth of shares (2,631 units at $6.60) (SEC Form 4)

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/26/25 4:30:14 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Good Jennifer L exercised 5,263 shares at a strike of $1.43 and sold $34,625 worth of shares (5,263 units at $6.58) (SEC Form 4)

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/25/25 4:30:04 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Sciascia Thomas

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/12/25 4:00:07 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.

      SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      5/15/25 4:34:45 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Trevi Therapeutics Inc.

      10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)

      5/8/25 4:16:35 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

      5/8/25 4:12:52 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care